BioSpace News Archive

CooperCompanies announced it will report fourth quarter and full year 2023 financial results on Thursday, December 7, 2023, at 4:15 PM ET.

Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its third quarter 2023 financial results on Monday, November 13, 2023.

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company focused on developing targeted therapies designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the third quarter ended September 30, 2023 and provided an update on its corporate activities and product pipeline.

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the third quarter 2023 after market close on Wednesday, November 8th, 2023.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for third quarter 2023 and provided a business update.

Castle Biosciences, Inc. announced new data showing the ability of its pipeline test in development to distinguish between responders and non-responders to an atopic dermatitis therapy and also distinguish between AD, psoriasis and mycosis fungoides skin lesions.

MacroGenics, Inc., a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, announced that the Company’s management will participate in the following upcoming investor conferences.

Genezen, a leading cell and gene therapy Contract Development and Manufacturing Organization, announced the closing of an $18.5 million follow-on growth equity investment led by Ampersand Capital Partners.

Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the third quarter ended September 30, 2023, and provides a corporate update.

The MODIA® study didn’t meet the primary end-points, but showed high rates of treatment response in both study arms, with no adverse events associated with the use of MODIA.